Free access
Issue
Vet. Res.
Volume 36, Number 5-6, September-December 2005
Page(s) 827 - 838
DOI http://dx.doi.org/10.1051/vetres:2005033
How to cite this article Vet. Res. (2005) 827-838
References of Vet. Res. 36 827-838
  1. Armijos R.X., Weigel M.M., Aviles H., Maldonado R., Racines J., Field trial of a vaccine against New World cutaneous leishmaniasis an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up, J. Infect. Dis. 177 (1998) 1352-1357 [PubMed].
  2. Armijos R.X., Weigel M.M., Calvopina M., Hidalgo A., Cevallos W., Correa J., Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis, Vaccine 22 (2004) 1320-1326 [CrossRef] [PubMed].
  3. Bhatia A., Daifalla N.S., Jen S., Badaro R., Reed S.G., Skeiky Y.A., Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi, Mol. Biochem. Parasitol. 102 (1999) 249-261 [CrossRef] [PubMed].
  4. Boag P.R., Parsons J.C., Presidente P.J.A., Spithill T.W., Sexton J.L., Characterisation of humoral immune responses in dogs vaccinated with irradiated Ancylostoma caninum, Vet. Immunol. Immunopathol. 92 (2003) 87-94 [PubMed].
  5. Borja-Cabrera G.P., Correia Pontes N.N., Da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., Luz K.G., Palatnik M., Palatnik de Sousa C.B., Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN), Vaccine 20 (2002) 3277-3284 [CrossRef] [PubMed].
  6. Burns J.M. Jr., Shreffler W.G., Benson D.R., Ghalib H.W., Badaro R., Reed S.G., Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis, Proc. Natl. Acad. Sci. USA 90 (1993) 775-779 [PubMed].
  7. Camargo M.E., Fluorescent antibody test for the serodiagnosis of american trypanosomiasis. Technical modification employing preserved cultures forms of Trypanosoma cruzi in a slide test, Rev. Inst. Med. Trop. São Paulo 8 (1966) 227-234 [PubMed].
  8. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Skeiky Y.A., Reed S.G., Grimaldi G. Jr., Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and non-human primate models of the human disease, Infect. Immun. 69 (2001) 4103-4108 [CrossRef] [PubMed].
  9. Campos-Neto A., Webb J.R., Greeson K., Coler R.N., Skeiky Y.A.W., Reed S.G., Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice, Infect. Immun. 70 (2002) 2828-2836 [CrossRef] [PubMed].
  10. Cook J.A., Holbrook T.W., Parker B.W., Visceral leishmaniasis in mice: protective effect of glucan, J. Reticuloendothel. Soc. 27 (1980) 567-573 [PubMed].
  11. Chabalgoity J.A., Moreno M., Carol H., Dougan G., Hormaeche C.E., Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine, Vaccine 19 (2001) 460-469.
  12. Da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., De Souza E.P., Luz K.G., Palatnik M., Palatnik de Sousa C.B., A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN), Vaccine 19 (2000) 1082-1092 [CrossRef] [PubMed].
  13. De Luca P.M., Mayrink W., Alves C.R., Coutinho S.G., Oliveira M.P., Bertho A.L., Toledo V.P., Costa C.A., Genaro O., Mendonca S.C., Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis, Vaccine 17 (1999) 1179-1185 [CrossRef] [PubMed].
  14. Fallah E., Mohebali M., Zareh N.M., Preparation and evaluation of Leishmania vaccines in Iran for the control of kala-azar, Acta Parasitol. (Warsawa) 45 (2000) 202-203.
  15. Genaro O., Pinto J.A., Costa C.A., Franca-Silva J.C., Silva J.C., Sanguinetti L.S.R., Vieira E.P., Toledo V.P.C.P., Mayrink W., Phase III randomized double blind clinical trial of the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG, Brazil, Mem. Inst. Oswaldo Cruz 91 (1996) 166.
  16. Gavgani A.S.M., Mohite H., Edrissian G.H., Mohebali M., Davies C.R., Domestic dog ownership in Iran is a risk factor for human infection with Leishmania infantum, Am. J. Trop. Med. Hyg. 65 (2002) 511-515.
  17. Goto H., Lindoso J.A., Immunity and immunosuppression in experimental visceral leishmaniasis, Braz. J. Med. Biol. Res. 37 (2004) 615-623 [PubMed].
  18. Gradoni L., An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine, Vet. Parasitol. 100 (2001) 87-103 [CrossRef] [PubMed].
  19. Guerin P.J., Olliaro P., Sundar S., Boelaert M., Croft S.L., Desjeux P., Wasunna M.K., Bryceson A.D.M., Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda, Lancet Infect. Dis. 2 (2002) 494-501 [PubMed].
  20. Handman E., Leishmaniasis: current status of vaccine development, Clin. Microbiol. Rev. 14 (2001) 229-243 [CrossRef] [PubMed].
  21. Heppner D.G., Gordon D.M., Gross M., Wellde B., Leitner W., Kzych U., Schneider I., Wirtz R.A., Richards R.L., Trofa A., Hall T., Sadoff J.C., Boerger P., Alving C.R., Sylvester D.R., Porter T.G., Ballou W.R., Safety, immunogenicity and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes, J. Infect. Dis. 174 (1996) 361-366 [PubMed].
  22. Holbrook T.W., Cook J.A., Parker B.W., Immunization against Leishmania donovani: glucan as an adjuvant with killed promastigotes, Am. J. Trop. Med. Hyg. 30 (1981) 762-768 [PubMed].
  23. Marzochi K.B., Marzochi M.A., Silva A.F., Grativol N., Duarte R., Confort E.M., Modabber F., Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil, Mem. Inst. Oswaldo Cruz 93 (1998) 205-212.
  24. Mauricio I.L., Howard M.K., Stothard J.R., Miles M.A., Genomic diversity in the Leishmania donovani complex, Parasitology 119 (1999) 237-246 [CrossRef] [PubMed].
  25. Mayrink W., Costa C.A., Magalhaes P.A., Melo M.N., Dias M., Lima A.O., Michalick M.S., Williams P., A field trial of a vaccine against American dermal leishmaniasis, Trans. R. Soc. Trop. Med. Hyg. 73 (1979) 385-387 [CrossRef] [PubMed].
  26. Mayrink W., Williams P., Costa C.A., Dias M., An experimental vaccine against American dermal leishmaniasis: experience in the state of Espirito Santo, Brazil, Ann. Trop. Med. Parasitol. 79 (1985) 259-269 [PubMed].
  27. Mayrink W., Antunes C.M.G., Costa C.A., Melo M.N., Dias M., Michalick M.S., Magalhaes P.A., De Oliveira Lima A., Williams P., Further trials of a vaccine against American cutaneous leishmaniasis, Trans. R. Soc. Trop. Med. Hyg. 80 (1986) 1001.
  28. Mayrink W., Genaro O., Franca-Silva J.C., da Costa R.T., Tafuri W.F., Toledo V.P., da Silva A.R., Reis A.B., Williams P., da Costa P.W., Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs, Mem. Inst. Oswaldo Cruz 91 (1996) 695-697 [PubMed].
  29. Mayrink W., Santos G.C., Toledo V.P.C.P., Guimaraes T.M., Machado-Coelho G.L., Genaro O., da Costa C.A., Vaccination of C57BL/10 mice against cutaneous leishmaniasis using killed promastigotes of different strains and species of Leishmania, Rev. Soc. Bras. Med. Trop. 35 (2002) 125-132 [PubMed].
  30. Mendez S., Gurunathan S., Kamhawi S., Belkaid Y., Moga M.A., Skeiky Y.A., Campos-Neto A., Reed S., Seder R.A., Sacks D., The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge, J. Immunol. 166 (2001) 5122-5128 [PubMed].
  31. Mendez S., Belkaid Y., Seder R.A., Sacks D., Optimization of DNA vaccination against cutaneous leishmaniasis, Vaccine 20 (2002) 3702-3708 [CrossRef] [PubMed].
  32. Modabber F., Vaccines against leishmaniasis, Ann. Trop. Med. Parasitol. 89 (1995) 83-88 [PubMed].
  33. Mohebali M., Fallah E., Jamshidi S., Hajjaran H., Vaccine trial against canine visceral leishmaniasis in the Islamic Republic of Iran, Rev. Santé Méditerranée Orientale 4 (1998) 234-238.
  34. Mohebali M., Fallah E., Mobedi I., Hajjaran H., Field trial of autoclaved Leishmania vaccines for control of canine visceral leishmaniasis in Meshkin-Shahr, Iran, Arch. Razi Inst. 50 (1999) 87-92.
  35. Murray H.W., Hariprashad J., Coffman R.L., Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model, J. Exp. Med. 185 (1997) 867-874 [CrossRef] [PubMed].
  36. Nascimento E., Mayrink W., Costa C.A., Michalick M.S., Melo M.N., Barros G.C., Dias M., Antunes C.M., Lima M.S., Taboada D.C., Liu T.Y., Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses, Infect. Immun. 58 (1990) 2198-2203 [PubMed].
  37. Nieto C.G., García-Alonso M., Requena J.M., Mirón C., Soto M., Alonso C., Navarrete I., Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis, Vet. Immunol. Immunopathol. 67 (1999) 117-130 [PubMed].
  38. Oliveira-Mendes C., Paraguai de Souza E., Borja-Cabrera G.P., Maria Melo Batista L., Aparecida dos Santos M., Ellner Parra L., Menz I., Palatnik M., Palatnik de Sousa C.B., IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis, Vaccine 21 (2003) 2589-2597 [CrossRef] [PubMed].
  39. Skeiky Y.A.W., Guderian J.A., Benson D.R., Bacelar O., Carvalho E.M., Kubin M., Badaro R., Trinchieri G., Reed S.G., A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12, J. Exp. Med. 181 (1995) 1527-1537 [CrossRef] [PubMed].
  40. Skeiky Y.A.W., Kennedy M., Kaufman D., Borges M.M., Guderian J.A., Scholler J.K., Ovendale P.J., Picha K.S., Morrissey P.J., Grabstein K.H., Campos-Neto A., Reed S.G., LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile, J. Immunol. 161 (1998) 6171-6179 [PubMed].
  41. Skeiky Y.A.W., Coler R.N., Brannon M., Stromberg E., Greeson K., Crane R.T., Webb J.R., Campos-Neto A., Reed S.G., Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL® adjuvant, Vaccine 20 (2002) 3292-3303 [CrossRef] [PubMed].
  42. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., Glenn G., Ockenhouse C.F., Garcon N., Schwenk R., Lanar D.E., Sun P., Momin P., Wirtz R.A., Golenda C., Slaoui M., Wortmann G., Holland C., Dowler M., Cohen J., Ballou W.R., Long-term efficacy and immune responses following immunization with the RTS, S malaria vaccine, J. Infect. Dis. 178 (1998) 1139-1144 [PubMed].
  43. Ulrich J.T., Myers K.R., Monophosphoryl lipid A as an adjuvant. Past experiences and new directions, in: Powell M.F., Newman M.J. (Eds.), Vaccine design: the subunit and adjuvant approach, Plenum Press, New York, 1995, p. 495.
  44. Webb J.R., Kaufman D., Campos-Neto A., Reed S.G., Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis, J. Immunol. 157 (1996) 5034-5041 [PubMed].
  45. Webb J.R., Campos-Neto A., Skeiky Y.A.W., Reed S.G., Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major, Mol. Biochem. Parasitol. 89 (1997) 179-193 [CrossRef] [PubMed].
  46. Webb J.R., Campos-Neto A., Ovendale P., Martin T.I., Stromberg E.J., Badaro R., Reed S.G., Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family, Infect. Immun. 66 (1998) 3279-3289 [PubMed].